Dr Reddy's fixes July 23 for AGM, recommends Rs 8 dividend
Dr Reddy's Laboratories has scheduled its 42nd Annual General Meeting for July 23, 2026, via video conference, recommending a final dividend of Rs 8 per share for FY26. The record date for dividend entitlement is July 10, 2026. The company detailed TDS regulations, requiring shareholders to submit necessary documents by June 30, 2026, to ensure correct tax deduction.
*this image is generated using AI for illustrative purposes only.
Dr Reddy's Laboratories has scheduled its 42nd Annual General Meeting (AGM) for Thursday, July 23, 2026, at 11.00 a.m. IST via video conference. The Board of Directors has recommended a final dividend of Rs 8 per equity share of face value Rs 1 each for the financial year ended March 31, 2026. Shareholders must ensure their bank details are updated to receive the dividend payment electronically on or before July 30, 2026.
The company has fixed Friday, July 10, 2026, as the record date to determine the entitlement of members to the final dividend, subject to approval at the AGM. The notice for the AGM and the Integrated Annual Report for FY26 will be sent electronically to shareholders who have registered their email addresses with the company or depository participants. Physical copies will not be dispatched.
Shareholders can participate in the AGM only through video conferencing or other audio-visual means, and their attendance will count towards the quorum. A remote e-voting facility will be available for members to cast their votes prior to or during the meeting. Detailed procedures for e-voting and joining the virtual meeting will be provided in the notice.
The company has outlined tax deduction at source (TDS) regulations applicable to dividend income effective from April 1, 2026. For resident shareholders with a valid PAN, the TDS rate is 10%, while it rises to 20% for those without a valid PAN or with an inoperative PAN. No tax will be deducted if the total dividend income does not exceed Rs 10,000 during the tax year 2026-27.
Non-resident shareholders will be subject to TDS at 20% plus applicable surcharge and cess, unless they opt for benefits under the Double Tax Avoidance Treaty (DTAA). To avail DTAA benefits, non-resident shareholders must submit a self-attested Tax Residency Certificate, PAN details, and Form 41. Shareholders must submit all necessary documents to the Registrar and Transfer Agent by 11.59 pm IST on June 30, 2026, to ensure the correct tax rate is applied.
| Shareholder Category | TDS Rate |
|---|---|
| Resident with valid PAN | 10% |
| Resident without PAN/Invalid PAN | 20% |
| Non-Resident (without DTAA) | 20% + surcharge & cess |
Historical Stock Returns for Dr Reddys Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.46% | +1.20% | -3.33% | +0.98% | -2.67% | +22.18% |
How will the shift to a fully virtual AGM format impact shareholder engagement and voting participation compared to traditional physical meetings?
What does the recommended dividend of Rs 8 per share indicate about Dr Reddy's free cash flow and capital allocation strategy for FY26?
Could the new TDS regulations effective April 1, 2026, influence dividend yield attractiveness for foreign institutional investors?
20
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
